ERBB2 and breast cancer: In this retrospective single-center study with data from 3 pooled clinical trials, we observed a positive association between the HER2/CEP17 FISH ratio and pCR among patients with HER2+ breast cancer who received a neoadjuvant anti-HER2 doublet treatment regimen without conventional chemotherapy.